Spots Global Cancer Trial Database for A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia
Official Title: An Open-Label Single and Multiple-dose, Study to Evaluate Safety, Tolerability and Efficacy of ABI-2280 Vaginal Tablet in Participants With Cervical Squamous Intraepithelial Lesions
Study ID: NCT05502367
Conditions
Interventions
Study Description
Brief Summary: This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B. Part A consists of 3 dose escalating cohorts. Part B is a dose expansion cohort. Participants will self-administer ABI-2280.
Detailed Description:
Keywords
Eligibility
Minimum Age: 25 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
East Sydney Doctors, Darlinghurst, New South Wales, Australia
Gold Coast University Hospital, Southport, Queensland, Australia
Farmvos, Bloemfontein, Free State, South Africa
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
